p. 2338 - 2339
(2003)p. 2345 - 2350
(2021/05/17)p. 6246 - 6251
(2019/12/03)(2019/05/10)
p. 1067 - 1078
(2018/08/01)p. 4290 - 4294
(2017/04/03)p. 3341 - 3348
(2014/06/10)p. 12357 - 12362
(2012/11/07)p. 5454 - 5460
(2012/08/27)p. 1087 - 1095
(2011/07/09)p. 3454 - 3456
(2007/10/03)(2008/06/13)
(2008/06/13)
(2008/06/13)
p. 5195 - 5198
(2007/10/03)p. 852 - 854
(2007/10/03)p. 10309 - 10320
(2007/10/02)(2008/06/13)
(2008/06/13)
(2008/06/13)
(2008/06/13)
(2008/06/13)
p. 269 - 273
(2007/10/02)p. 4985 - 4986
(2007/10/02)p. 2045 - 2062
(2007/10/02)p. 1447 - 1450
(2007/10/02)p. 1399 - 1402
(2007/10/02)p. 7729 - 7734
(2007/10/02)p. 2274 - 2278
(2007/10/02)p. 2279 - 2284
(2007/10/02)(2008/06/13)
(2008/06/13)
u-2-amino-1-phenylpropan-1-ol
pivalaldehyde
(4R,5S)-2,2,4-Trimethyl-5-phenyl-oxazolidine
cyclohexanecarbaldehyde
S-(carboxymethyl)-(RS)-cysteine
(1S,2R)-(+)-1-phenyl-2-(1-pyrrolidinyl)-1-propanol
2,2-Dichloro-N-((1R,2S)-2-hydroxy-1-methyl-2-phenyl-ethyl)-acetamide
(1S,2R)-(+)-2-(N,N-bis(2-phenylethyl)amino)-1-phenylpropan-1-ol
(2R,3S,4R,5S)-3-Benzyl-4-methyl-5-phenyl-2-((E)-styryl)-oxazolidine
(4R,5S)-4-methyl-2,5-diphenyl-1,3,2-oxazaboroline